✦ LIBER ✦

Absence of Galectin-1 accelerates CD8+ T cell-mediated graft rejection

✍ Scribed by Aurélie Moreau; Alistair Noble; Kulachelvy Ratnasothy; Jian-Guo Chai; Louise Deltour; Maria-Cristina Cuturi; Elizabeth Simpson; Robert Lechler; Giovanna Lombardi

Book ID: 115555245
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 893 KB
Volume: 42
Category: Article
ISSN: 0014-2980
DOI: 10.1002/eji.201142325

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cross-primed CD8+ T cells mediate graft

Cross-primed CD8+ T cells mediate graft rejection via a distinct effector pathway

✍ Valujskikh, Anna; Lantz, Olivier; Celli, Susanna; Matzinger, Polly; Heeger, Pete 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 812 KB

A role for Th2 cytokines in the suppress

A role for Th2 cytokines in the suppression of CD8+ T cell-mediated graft rejection

✍ Ralph Scully; Stephen P. Cobbold; Andrew L. Mellor; Martin Wissing; Bernd Arnold 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 803 KB

Role of 4-1BB in Allograft Rejection Med

Role of 4-1BB in Allograft Rejection Mediated by CD8+ T Cells

✍ Jun Wang; Zhong Guo; Ying Dong; Oliver Kim; John Hart; Andrew Adams; Christian P 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 742 KB

Galectin-1: a key effector of regulation

Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells

✍ Garin, M. I.; Chu, C.-C.; Golshayan, D.; Cernuda-Morollon, E.; Wait, R.; Lechler 📂 Article 📅 2006 🏛 American Society of Hematology 🌐 English ⚖ 327 KB

RANTES is produced by CD8+ T cells durin

RANTES is produced by CD8+ T cells during acute rejection of skin grafts

✍ S Koga; A Kapoor; A.C Novick; H Toma; R.L Fairchild 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 59 KB

CD4+ T cell-mediated HER-2/neu-specific

CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells

✍ Jan Alvar Lindencrona; Susanne Preiss; Thomas Kammertoens; Thomas Schüler; Marie 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 134 KB

## Abstract HER‐2/neu (HER‐2) is a cell surface proto‐oncogene that is often overexpressed in carcinomas. Passive administration of anti‐HER‐2 antibodies in breast cancer patients has achieved promising results, but less is known about the role of antibodies in active immunization. We asked whether